Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

LaNova Medicines Announces IND Approval of LM-317 by US FDA

  • 2024-06-10

  • Share:

SHANGHAI, June 10th, 2024 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-317, an anti-NaPi2b antibody drug conjugate (ADC), has been approved by the US Food and Drug Administration (FDA).